Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics/Pharmacodynamics of NOX-H94 in the Human Endotoxemia Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Main Inclusion Criteria:~* BMI between 18 and 30 kg/m², with a lower limit of body weight of 50 kg~* Healthy as determined by medical history, physical examination, vital signs, 12 lead electrocardiogram, and clinical laboratory parameters~* Serum iron and red blood parameters Hb, MCV, ferritin, serum iron, and total iron binding capacity within reference range~Main Exclusion Criteria:~* Use of any medication, recreational drugs or anti-oxidant vitamin supplements within 7 days~* Use of caffeine, nicotine, or alcohol within 1 day~* Previous participation in a trial where LPS was administered~* Surgery or trauma with significant blood loss or blood donation within 3 months~* History, signs or symptoms of cardiovascular disease (vaso-vagal collapse or of orthostatic hypotension, Resting pulse rate ≤45 or ≥100/min, Hypertension, Hypotension, ECG conduction abnormalities)~* Renal impairment: plasma creatinine \>120 µmol/L~* Liver function tests (alkaline phosphatase, AST, ALT and γ-GT) outside of the reference range or total bilirubin \>20 µmol/L~* Hemoglobin or iron parameters (iron, transferring saturation, ferritin) outside of the reference ranges~* History of asthma~* Immuno-deficiency~* Positive test of HIV type 1/2 antibodies, HBs antigen, HBc antibodies and HCV antibodies unless antibody titer is induced by vaccination~* CRP \> reference range or clinically significant acute illness, including infections, within 2 weeks~* Treatment with investigational drugs or participation in any other clinical trial within 30 days prior to study drug administration~* Known or suspected of not being able to comply with the trial protocol~* Inability to personally provide written informed consent and/or take part in the study

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- NOX-H94 (Type: EXPERIMENTAL): Single dose of NOX-H94
- Placebo (Type: PLACEBO_COMPARATOR): Single dose of placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).